## Helen A Petousis-Harris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/525798/publications.pdf

Version: 2024-02-01

58 papers

1,223 citations

430874 18 h-index 395702 33 g-index

59 all docs 59 docs citations

59 times ranked

1428 citing authors

#	Article	IF	CITATIONS
1	Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet, The, 2017, 390, 1603-1610.	13.7	303
2	Vaccine injection technique and reactogenicity—Evidence for practice. Vaccine, 2008, 26, 6299-6304.	3.8	53
3	Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open, 2016, 6, e009536.	1.9	50
4	Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine, 2018, 36, 5173-5179.	3.8	49
5	Impact of meningococcal group B OMV vaccines, beyond their brief. Human Vaccines and Immunotherapeutics, 2018, 14, 1058-1063.	3.3	46
6	Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine, 2020, 38, 4362-4373.	3.8	46
7	Recruitment of practices in primary care research: the long and the short of it. Family Practice, 2009, 26, 128-136.	1.9	43
8	Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study. Vaccines, 2019, 7, 5.	4.4	43
9	Family physician perspectives on barriers to childhood immunisation. Vaccine, 2004, 22, 2340-2344.	3 <b>.</b> 8	39
10	Family practice nurse views on barriers to immunising children. Vaccine, 2005, 23, 2725-2730.	3.8	39
11	Safety of Tdap vaccine in pregnant women: an observational study. BMJ Open, 2016, 6, e010911.	1.9	38
12	Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Safety, 2020, 43, 1205-1210.	3 <b>.</b> 2	34
13	Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines. Frontiers in Immunology, 2019, 10, 683.	4.8	30
14	Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries. PLoS ONE, 2020, 15, e0233334.	2.5	27
15	Factors associated with immunisation coverage and timeliness in New Zealand. British Journal of General Practice, 2010, 60, e113-e120.	1.4	24
16	Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance. Vaccine, 2012, 30, 4945-4952.	3.8	21
17	Seize the moments: missed opportunities to immunize at the family practice level. Family Practice, 2009, 26, 275-278.	1.9	19
18	Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand. Vaccine, 2017, 35, 177-183.	3.8	19

#	Article	IF	Citations
19	A Qualitative Study of Views and Experiences of Women and Health Care Professionals about Free Maternal Vaccinations Administered at Community Pharmacies. Vaccines, 2020, 8, 152.	4.4	18
20	MeNZBâ,,¢ vaccine and epidemic control: When do you stop vaccinating?. Vaccine, 2008, 26, 5899-5904.	3.8	17
21	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. Journal of Primary Health Care, 2012, 4, 12.	0.6	17
22	Immunization in the Print Mediaâ€"Perspectives Presented by the Press. Journal of Health Communication, 2007, 12, 759-770.	2.4	16
23	Human papillomavirus vaccination in Auckland: Reducing ethnic and socioeconomic inequities. Vaccine, 2012, 31, 84-88.	3.8	16
24	Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006–2015. Clinical Infectious Diseases, 2019, 68, 818-826.	5.8	16
25	Influences on Pregnant Women's and Health Care Professionals' Behaviour Regarding Maternal Vaccinations: A Qualitative Interview Study. Vaccines, 2022, 10, 76.	4.4	15
26	Follow-up of MMR Vaccination Status in Children Referred to a Pediatric Immunization Clinic on Account of Egg Allergy. Hum Vaccin, 2005, 1, 118-122.	2.4	12
27	Determining immunisation coverage rates in primary health care practices: A simple goal but a complex task. International Journal of Medical Informatics, 2008, 77, 477-485.	3.3	12
28	An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: A randomized trial. Vaccine, 2013, 31, 1157-1162.	3.8	12
29	A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. Vaccines, 2019, 7, 147.	4.4	12
30	Primary care practice and health professional determinants of immunisation coverage. Journal of Paediatrics and Child Health, 2011, 47, 541-549.	0.8	11
31	Measuring disparities in immunisation coverage among children in New Zealand. Health and Place, 2012, 18, 1217-1223.	3.3	11
32	Fever following administration of two inactivated influenza vaccinesâ€"A survey of parents of New Zealand infants and children 5 years of age and under. Vaccine, 2011, 29, 2933-2937.	3.8	10
33	Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents. Human Vaccines and Immunotherapeutics, 2015, 11, 1872-1877.	3.3	10
34	Proposed HPV vaccination syndrome is unsubstantiated. Clinical Rheumatology, 2016, 35, 833-834.	2.2	10
35	Increasing Uptake of Maternal Pertussis Vaccinations through Funded Administration in Community Pharmacies. Vaccines, 2022, 10, 150.	4.4	9
36	Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. BMJ Global Health, 2021, 6, e003540.	4.7	8

#	Article	IF	CITATIONS
37	The cost of immunising at the general practice level. Journal of Primary Health Care, 2009, 1, 286.	0.6	8
38	Fact or fallacy? Immunisation arguments in the New Zealand print media. Australian and New Zealand Journal of Public Health, 2010, 34, 521-526.	1.8	7
39	Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. New Zealand Medical Journal, 2020, 133, 112-118.	0.5	7
40	Immunization champions: Characteristics of general practitioners associated with better immunization delivery. Hum Vaccin, 2009, 5, 403-411.	2.4	6
41	The use and misuse of media headlines: lessons from the MeNZB immunisation campaign. New Zealand Medical Journal, 2009, 122, 22-7.	0.5	6
42	Early connections: effectiveness of a pre-call intervention to improve immunisation coverage and timeliness. Journal of Primary Health Care, 2012, 4, 189.	0.6	5
43	Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and intussusception in New Zealand: A retrospective cohort study. Vaccine, 2020, 38, 1730-1739.	3.8	4
44	Progress Toward a Global Vaccine Data Network. Pediatric Infectious Disease Journal, 2020, 39, 1023-1025.	2.0	4
45	Back to Back: Saturated fat has been unfairly demonised: Yes. Journal of Primary Health Care, 2011, 3, 317.	0.6	3
46	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. Journal of Primary Health Care, 2012, 4, 12-20.	0.6	3
47	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol. Vaccines, 2022, 10, 309.	4.4	3
48	The New Zealand national immunisation hotlineâ€"what are callers seeking?. Vaccine, 2005, 23, 5038-5044.	3.8	2
49	Comparison of vaccination coverage of four childhood vaccines in New Zealand and New York State. Journal of Paediatrics and Child Health, 2019, 55, 781-788.	0.8	2
50	Reply to "Comment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study, Vaccines, 2019, 1, 5; doi:10.3390/vaccines7010005― Vaccines, 2019, 7, 32.	4.4	1
51	Impact of antivaccination campaigns on health worldwide: lessons for Australia and the global community. Medical Journal of Australia, 2020, 213, 300.	1.7	1
52	Needle angle when giving i.m. vaccinations. Nursing Praxis in New Zealand, 2002, 18, 52-3.	0.2	1
53	Recommendation to take a holistic view of the dynamic pathogenic pneumococcal environment. Clinical Infectious Diseases, 2022, , .	5.8	1
54	Cherry picked case reports are not scientific evidence in the face of large clinical and epidemiological studies. Clinical Rheumatology, 2016, 35, 837-838.	2,2	0

#	Article	IF	CITATIONS
55	Author reply to VA-MENGOC-BC cross-protection (2018HV0022). Human Vaccines and Immunotherapeutics, 2018, 14, 1069-1069.	3.3	0
56	Pitfalls of the healthy vaccinee effect – Authors' reply. Lancet, The, 2018, 391, 123-124.	13.7	0
57	Pertussis Vaccination Failure in the New Zealand Pediatric Population: Study Protocol. Vaccines, 2019, 7, 65.	4.4	0
58	Saturated fat has been unfairly demonised: yes. Journal of Primary Health Care, 2011, 3, 317-9.	0.6	0